Dioxin and immune regulation: Emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells

Annals of the New York Academy of Sciences

Volumn 1183, Issue , 2010, Pages 25-37

  Marshall, Nikki B ^a   Kerkvliet, Nancy I ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

2,3,7,8 tetrachlorodibenzo p dioxin; Aryl hydrocarbon receptor; Dendritic cells; Foxp3; Indoleamine 2,3 dioxygenase; NF B; Regulatory T cells

Indexed keywords

3 INDOLEMETHANOL; AROMATIC HYDROCARBON RECEPTOR; DIOXIN; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOL DERIVATIVE; RESVERATROL; TRANILAST; TRANSCRIPTION FACTOR FOXP3;

B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTOXICITY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 75749087979     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05125.x     Document Type: Review

References (112)

1. Huwe, J.K. 2002. Dioxins in food: A modern agricultural perspective. J. Agric. Food Chem. 50: 1739-1750.
2. Aylward, L.L. & S.M. Hays. 2002. Temporal trends in human TCDD body burden: Decreases over three decades and implications for exposure levels. J. Expo. Anal. Environ Epidemiol 12: 319-328.
3. Institute ofMedicine. 2007. Veterans and Agent Orange: Update 2006. National Academies Press. Washington D.C.
4. Schecter,A.&T.A. Gasiewicz. 2003. Dioxins andHealth. 2nd Edition. JohnWiley and Sons, Inc.Hoboken,NJ.
5. Poland,A., E. Glover&A.S.Kende. 1976. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-pdioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. 251: 4936-4946.
6. Okey, A.B. 2007. An aryl hydrocarbon receptor odyssey to the shores of toxicology: The Deichmann Lecture, International Congress of Toxicology-XI. Toxicol Sci. 98: 5-38.
7. Nebert, D.W. et al. 2000. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 59: 65-85.
8. Burbach, K.M., A. Poland & C.A. Bradfield. 1992. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. USA 89: 8185-8189.
9. Fukunaga, B.N. et al. 1995. Identification of functional domains of the arylhydrocarbon receptor. J. Biol.Chem. 270: 29270-29278.
10. Jones, S. 2004.An overview of the basic helix-loop-helix proteins. Genome Biol. 5: 226.
11. Coumailleau, P. et al. 1995. Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity. J. Biol. Chem. 270: 25291-25300
12. Goryo, K. et al. 2007. Identification of amino acid residues in the Ah receptor involved in ligand binding. Biochem Biophys Res Commun. 354: 396-402.
13. Kumar, M.B. et al. 2001. The Q-rich subdomain of the human Ah receptor transactivation domain is required for dioxin-mediated transcriptional activity. J. Biol. Chem. 276: 42302-42310.
14. Beischlag, T.V. et al. 2008. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot Gene. Expr. 18: 207-250.
15. Shen, E.S. & J.P. Whitlock, Jr. 1992. Protein-DNA interactions at a dioxin-responsive enhancer. Mutational analysis of the DNA-binding site for the liganded Ah receptor. J. Biol. Chem. 267: 6815-6819.
16. Hahn, M.E., L.L. Allan & D.H. Sherr. 2009. Regulation of constitutive and inducibleAHRsignaling:Complex interactions involving the AHR repressor. Biochem Pharmacol 77: 485-497.
17. Bunger, M.K. et al. 2008. Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNAbinding domain of the aryl hydrocarbon receptor. Toxicol Sci. 106: 83-92.
18. Kim, D.W. et al. 2000. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 19: 5498-5506.
19. Tian, Y. et al. 1999. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J. Biol. Chem. 274: 510-515.
20. Puga, A. et al. 2000. Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. J. Biol. Chem. 275: 2943-2950.
21. Klinge, C.M., K. Kaur & H.I. Swanson. 2000. The aryl hydrocarbon receptor interacts with estrogen receptor alpha and orphan receptors COUP-TFI and ERRalpha1. Arch. Biochem Biophys. 373: 163-174.
22. Ohtake, F. et al. 2003. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423: 545-550.
23. Ohtake, F. et al. 2007. Dioxin receptor is a liganddependent E3 ubiquitin ligase. Nature 446: 562-566.
24. Kerkvliet, N.I. 2002. Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int. Immunopharmacol 2: 277-291.
25. Lawrence, B.P. & N.I. Kerkvliet. 2007. Immune modulation by TCDD and related polyhalogenated aromatic hydrocarbons. In Immunotoxicology and Immunopharmacology. Luebke, R., R. House & I. Kimber, Eds.: 239-258. CRC Press. Boca Raton, FL.
26. Kerkvliet, N.I. 1994. Immunotoxicology ofDioxins and Related Chemicals. In Dioxins and Health. Schecter,A., Ed. Plenum Press. New York.
27. Vorderstrasse, B.A. et al. 2001. Aryl hydrocarbon receptor-deficient mice generate normal immune responses to model antigens and are resistant to TCDDinduced immune suppression. Toxicol Appl Pharmacol 171: 157-164.
28. Fernandez-Salguero, P.M. et al. 1996. Arylhydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol. Appl. Pharmacol. 140: 173-179.
29. Staples, J.E. et al. 1998. Thymic alterations induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are strictly dependent on aryl hydrocarbon receptor activation in hemopoietic cells. J. Immunol 160: 3844-3854.
30. Sun, Y.V. et al. 2004. Comparative analysis of dioxin response elements in human, mouse and rat genomic sequences. Nucleic. Acids. Res. 32: 4512-4523.
31. Head, J.L. & B.P. Lawrence. 2009. The aryl hydrocarbon receptor is amodulator of anti-viralimmunity. Biochem Pharmacol 77: 642-653.
32. Vorderstrasse, B.A. & N.I. Kerkvliet. 2001. 2,3,7,8- Tetrachlorodibenzo-p-dioxin affects the number and function of murine splenic dendritic cells and their expression of accessory molecules. Toxicol. Appl. Pharmacol 171: 117-125.
33. Vorderstrasse, B.A., E.A. Dearstyne & N.I. Kerkvliet. 2003. Influence of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the antigen-presenting activity of dendritic cells. Toxicol Sci. 72: 103-112.
34. Lee, J.A. et al. 2007. 2,3,7,8-Tetrachlorodibenzo-pdioxin modulates functional differentiation of mouse bone marrow-derived dendritic cells Downregulation of RelB by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Lett. 173: 31-40.
35. Ruby, C.E., C.J. Funatake & N.I. Kerkvliet. 2005. 2,3,7,8 Tetrachlorodibenzo-p-Dioxin (TCDD) directly enhances the maturation and apoptosis of dendritic cells in vitro. J. Immunotoxicol 1: 159-166.
36. Ruby, C.E., M. Leid & N.I. Kerkvliet. 2002. 2,3,7,8- Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: P50 homodimer activation is not affected. Mol. Pharmacol. 62: 722-728.
37. Vogel, C.F. & F.Matsumura. 2009. A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB family. Biochem Pharmacol. 77: 734-745.
38. Puccetti, P. & U. Grohmann. 2007. IDO and regulatory T cells: A role for reverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol. 7: 817-823.
39. Ziegler-Heitbrock, L. 2001. The p50-homodimer mechanism in tolerance to LPS. J. Endotoxin. Res. 7: 219-222.
40. Fan, H. & J.A. Cook. 2004. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10: 71-84.
41. + T cells. J. Biol. Chem. 279: 8460-8468.
42. Bonizzi, G. & M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
43. Vogel, C.F. et al. 2007. RelB, a new partner of aryl hydrocarbon receptor-mediated transcription. Mol. Endocrinol 21: 2941-2955.
44. Thatcher, T.H. et al. 2007. Aryl hydrocarbon receptordeficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-kappaB component RelB. Am. J. Pathol. 170: 855-864.
45. Tas, S.W. et al. 2007. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3- dioxygenase (IDO) induction and immune regulation. Blood 110: 1540-1549.
46. Mellor, A.L. et al. 2004. Specific subsets ofmurine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol 16: 1391-1401.
47. + T regulatory cells. Blood 109: 2871-2877.
48. Belladonna, M.L. et al. 2007. Immunosuppression via tryptophan catabolism:The role of kynurenine pathway enzymes. Transplantation 84: S17-S20.
49. + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol 172: 4100-4110.
50. Fallarino, F. et al. 2003. Modulation of tryptophan catabolism by regulatoryTcells.Nat. Immunol. 4: 1206-1212.
51. Grohmann, U. et al. 2007. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat. Med. 13: 579-586.
52. + regulatory T cells. Nat. Immunol 4: 330-336.
53. Hori, S., T. Nomura & S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
54. Vogel, C.F. et al. 2008. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3- dioxygenase. Biochem Biophys Res. Commun 375: 331-335.
55. Lawrence, B.P. et al. 2008. Activation of the aryl hydrocarbon receptor is essential for mediating the antiinflammatory effects of a novel low-molecular-weight compound. Blood 112: 1158-1165.
56. Hauben, E. et al. 2008. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 112: 1214-1222.
57. Karras, J.G. & M.P. Holsapple. 1994. Mechanisms of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced disruption of B-lymphocyte signaling in the mouse: A current perspective. Exp. Clin. Immunogenet 11: 110-118.
58. Dooley, R.K. & M.P. Holsapple. 1988. Elucidation of cellular targets responsible for tetrachlorodibenzo-pdioxin (TCDD)-induced suppression of antibody responses: I. The role of the B lymphocyte. Immunopharmacology 16: 167-180.
59. Luster, M.I. et al. 1988. Selective effects of 2,3,7,8- tetrachlorodibenzo-p-dioxin and corticosteroid on in vitro lymphocyte maturation. J. Immunol 140: 928-935.
60. + T cells is necessary for full suppression of a cytotoxic T lymphocyte response by TCDD. Toxicol Appl. Pharmacol 185: 146-152.
61. Shepherd, D.M., E.A. Dearstyne & N.I. Kerkvliet. 2000. The effects of TCDD on the activation of ovalbumin (OVA)-specific DO11.10 transgenic CD4(+) T cells in adoptively transferred mice. Toxicol. Sci. 56: 340-350.
62. Funatake,C.J. et al. 2004. Early consequences of 2,3,7,8- tetrachlorodibenzo-p-dioxin exposure on the activation and survival of antigen-specific T cells. Toxicol. Sci. 82: 129-142.
63. Camacho, I.A., M. Nagarkatti & P.S. Nagarkatti. 2002. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces Fas-dependent activation-induced cell death in superantigen-primed T cells. Arch. Toxicol. 76: 570-580.
64. Oughton, J.A. & N.I. Kerkvliet. 1999. Novel phenotype associated with in vivo activated CTL precursors. Clin. Immunol. 90: 323-333.
65. Kerkvliet, N.I. et al. 1996. Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8- tetrachlorodibenzo-p-dioxin. J. Immunol. 157: 2310-2319.
66. Prell, R.A. et al. 2000. CTL hyporesponsiveness induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin: Role of cytokines and apoptosis. Toxicol Appl. Pharmacol. 166: 214-221.
67. Warren, T.K., K.A. Mitchell & B.P. Lawrence. 2000. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppresses the humoral and cell-mediated immune responses to influenza A virus without affecting cytolytic activity in the lung. Toxicol Sci. 56: 114-123.
68. + T cells hyporesponsive to antigen. Toxicol Sci. 74: 74-84.
69. Lundberg,K., L. Dencker&K.O.Gronvik. 1992. 2,3,7,8- Tetrachlorodibenzo-p-dioxin (TCDD) inhibits the activation of antigen-specific T cells in mice. Int. J. Immunopharmacol. 14: 699-705.
70. Prell, R.A., J.A. Oughton & N.I. Kerkvliet. 1995. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on anti-CD3- induced changes in T-cell subsets and cytokine production. Int. J. Immunopharmacol 17: 951-961.
71. Pryputniewicz, S.J., M. Nagarkatti & P.S. Nagarkatti. 1998. Differential induction of apoptosis in activated and resting T cells by 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) and its repercussion on T cell responsiveness. Toxicology 129: 211-226.
72. Kerkvliet, N.I. 2009. AHR-mediated immunomodulation: The role of altered gene transcription. Biochem Pharmacol 77: 746-760.
73. Luebke, R.W. et al. 2001. Suppression of allergic immune responses to house dust mite (HDM) in rats exposed to 2,3,7,8-TCDD. Toxicol. Sci. 62: 71-79.
74. Fujimaki, H. et al. 2002. Effect of a single oral dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin on immune function in male NC/Nga mice. Toxicol. Sci. 66: 117-124.
75. Quintana, F.J. et al. 2008. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453: 65-71.
76. + cells in pancreatic lymphnodes. Immunotherapy 1: 539-547.
77. + cells with characteristics of regulatory T cells. J. Immunol. 175: 4184-4188.
78. Nohara, K. et al. 2002. Effects of 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD)onTcell-derived cytokine production in ovalbumin (OVA)-immunized C57Bl/6 mice. Toxicology 172: 49-58.
79. Inouye,K. et al. 2005.Tcell-derived IL-5 production is a sensitive target of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Chemosphere 60: 907-913.
80. Negishi,T. et al. 2005. Effects of aryl hydrocarbon receptor signaling on the modulation of TH1/TH2 balance. J. Immunol 175: 7348-7356.
81. Morales, J.L. et al. 2008. Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole- 4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3- [2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists.Chem. Res. Toxicol. 21: 472-482.
82. Nouri-Aria, K.T. & S.R. Durham. 2008. Regulatory T cells and allergic disease. Inflamm Allergy Drug. Targets. 7: 237-252.
83. + regulatory T cells generated in mice treated with 2,3,7, 8-tetrachlorodibenzo-p-dioxin. J. Immunol. 181: 2382-2391.
84. + T cells. J. Immunotoxicol 5: 81-91.
85. + Regulatory T Cells. J. Immunol. 172: 5986-5993.
86. Funatake, C.J. et al. 2009. Constitutive activation of aryl hydrocarbon receptor in T cells only enhances the downregulation of CD62L but does not alter expression of CD25 or suppress the allogeneic CTL response. J. Immunotoxicol 6: 194-203.
87. Nelson, B.H. 2004. IL-2, regulatory T cells, and tolerance. J. Immunol. 172: 3983-3988.
88. Furtado, G.C. et al. 2002. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196: 851-857.
89. Jeon, M.S. & C. Esser. 2000. The murine IL-2 promoter contains distal regulatory elements responsive to the Ah receptor, a member of the evolutionarily conserved bHLH-PAS transcription factor family. J. Immunol. 165: 6975-6983.
90. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
91. + regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J. Immunol. 180: 7112-7116.
92. Hill, J.A. et al. 2007. Foxp3 transcription-factordependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27: 786-800.
93. Frericks,M., M.Meissner & C. Esser. 2007.Microarray analysis of the AHRsystem: Tissue-specific flexibility in signal and target genes. Toxicol. Appl. Pharmacol. 220: 320-332.
94. Kimura, A. et al. 2008. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc. Natl. Acad. Sci. USA 105: 9721-9726.
95. Veldhoen, M. et al. 2008. The aryl hydrocarbon receptor links Th17-cell-mediated autoimmunity to environmental toxins. Nature 453: 106-109.
96. Tesmer, L.A. et al. 2008. Th17 cells in human disease. Immunol Rev. 223: 87-113.
97. Wilson, N.J. et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8: 950-957.
98. Bettelli, E. et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
99. Awasthi, A. & V.K. Kuchroo. 2009. Th17 cells: From precursors to players in inflammation and infection. Int. Immunol. 21: 489-498.
100. Wei, Y.D. et al. 1998. Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b] carbazole. Chem. Biol. Interact. 110: 39-55.
101. Jensen, B.A. et al. 2003. Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: An immunotoxicology study. Environ. Health. 2: 16.
102. Hollingshead, B.D. et al. 2008. Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. Cancer Res. 68: 3609-3617.
103. Bjeldanes, L.F. et al. 1991. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: Comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. USA 88: 9543-9547.
104. Amakura, Y. et al. 2008. Influence of food polyphenols on aryl hydrocarbon receptor-signaling pathway estimated by in vitro bioassay. Phytochemistry 69: 3117-3130.
105. Zhang, S., C. Qin & S.H. Safe. 2003. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: Effects of structure and cell context. Environ Health Perspect 111: 1877-1882.
106. Oberg, M. et al. 2005. Identification of the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, in cell culture medium, as a factor that controls the background aryl hydrocarbon receptor activity. Toxicol Sci. 85: 935-943.
107. Terness, P. et al. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenaseexpressing dendritic cells: Mediation of suppression by tryptophan metabolites. J. Exp. Med. 196: 447-457.
108. Bauer, T.M. et al. 2005. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: Tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int. 18: 95-100.
109. Frumento, G. et al. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196: 459-468.
110. Heath-Pagliuso, S. et al. 1998. Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry 37: 11508-11515.
111. Fallarino, F. et al. 2006. The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176: 6752-6761.
112. Platten, M. et al. 2005. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310: 850-855.